DK3419595T3 - Stabil flydende gonadotropinformulering - Google Patents

Stabil flydende gonadotropinformulering Download PDF

Info

Publication number
DK3419595T3
DK3419595T3 DK17707527.2T DK17707527T DK3419595T3 DK 3419595 T3 DK3419595 T3 DK 3419595T3 DK 17707527 T DK17707527 T DK 17707527T DK 3419595 T3 DK3419595 T3 DK 3419595T3
Authority
DK
Denmark
Prior art keywords
gonadotropine
formulation
stable liquid
stable
liquid
Prior art date
Application number
DK17707527.2T
Other languages
English (en)
Inventor
Helen Ulrika Sjögren
Charlotte Højer-Pedersen
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3419595(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of DK3419595T3 publication Critical patent/DK3419595T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK17707527.2T 2016-02-24 2017-02-24 Stabil flydende gonadotropinformulering DK3419595T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1603280.7A GB201603280D0 (en) 2016-02-24 2016-02-24 Stable liquid gonadotropin formulation
PCT/EP2017/054325 WO2017144659A1 (en) 2016-02-24 2017-02-24 Stable liquid gonadotropin formulation

Publications (1)

Publication Number Publication Date
DK3419595T3 true DK3419595T3 (da) 2021-03-29

Family

ID=55806922

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17707527.2T DK3419595T3 (da) 2016-02-24 2017-02-24 Stabil flydende gonadotropinformulering
DK20202758.7T DK3791860T5 (da) 2016-02-24 2017-02-24 Stabil væskeformig gonadotropinformulering

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK20202758.7T DK3791860T5 (da) 2016-02-24 2017-02-24 Stabil væskeformig gonadotropinformulering

Country Status (36)

Country Link
US (4) US10792334B2 (da)
EP (3) EP3791860B1 (da)
JP (3) JP6932710B2 (da)
KR (1) KR102756413B1 (da)
CN (2) CN108883061B (da)
AR (1) AR107782A1 (da)
AU (2) AU2017222292B2 (da)
BR (1) BR112018015166A2 (da)
CA (1) CA3012759A1 (da)
CL (1) CL2018001984A1 (da)
CO (1) CO2018007810A2 (da)
DK (2) DK3419595T3 (da)
EA (1) EA036383B1 (da)
ES (2) ES2862193T3 (da)
FI (1) FI3791860T3 (da)
GB (1) GB201603280D0 (da)
HR (2) HRP20210367T1 (da)
HU (2) HUE064432T2 (da)
IL (1) IL260626B2 (da)
JO (1) JOP20170046B1 (da)
LT (2) LT3791860T (da)
MA (2) MA43686B1 (da)
MD (2) MD3791860T2 (da)
MX (1) MX381709B (da)
MY (1) MY193138A (da)
PH (1) PH12018501688B1 (da)
PL (2) PL3791860T3 (da)
PT (2) PT3419595T (da)
RS (2) RS64929B1 (da)
SG (1) SG11201806140SA (da)
SI (2) SI3791860T1 (da)
TN (1) TN2018000284A1 (da)
TW (1) TWI755377B (da)
UA (1) UA123107C2 (da)
WO (1) WO2017144659A1 (da)
ZA (1) ZA201804944B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
WO2019164765A1 (en) * 2018-02-26 2019-08-29 Slayback Pharma Llc Ready-to-use dexmedetomidine compositions
BR112021006406A2 (pt) * 2018-10-02 2021-07-06 Innocore Tech Holding B V forma de dosagem de gonadotrofina coriônica humana (hcg) de liberação prolongada
CN112451652A (zh) * 2020-12-07 2021-03-09 苏州智核生物医药科技有限公司 一种重组人促甲状腺素注射液
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions
CN118209739A (zh) * 2024-03-19 2024-06-18 厦门宝太和瑞生物技术有限公司 促黄体生成素检测试剂盒
KR102821987B1 (ko) * 2024-10-24 2025-06-26 에이디텍 주식회사 베타 코어 단편 hCG를 유효성분으로 포함하는 난임 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2198299C (en) 1996-02-28 2000-05-02 Yuhei Abe Card holder-type balance display
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
CA2335340C (en) * 1998-07-23 2013-03-05 Eli Lilly And Company Fsh and fsh variant formulations, products and methods
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
ES2393233T3 (es) * 2007-11-01 2012-12-19 Merck Serono S.A. Formulaciones de LH líquidas
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
RS52106B (sr) 2008-02-08 2012-08-31 Biogenerix Ag Tečni preparat fsh
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
RU2561057C2 (ru) 2008-11-04 2015-08-20 Аска Фармасьютикал Ко., Лтд. Водная композиция, содержащая фолликулостимулирующий гормон
RU2553375C2 (ru) 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
WO2011108010A2 (en) 2010-03-05 2011-09-09 Intas Biopharmaceuticals Limited A thermostable liquid formulation of gonadotropins
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
HK1223559A1 (zh) * 2013-11-12 2017-08-04 Cadila Healthcare Limited 用於促性腺激素的配方
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Also Published As

Publication number Publication date
JP2021191760A (ja) 2021-12-16
JP6932710B2 (ja) 2021-09-08
PT3419595T (pt) 2021-03-29
PT3791860T (pt) 2023-12-15
US10792334B2 (en) 2020-10-06
EP3791860A1 (en) 2021-03-17
CN108883061A (zh) 2018-11-23
GB201603280D0 (en) 2016-04-13
EP4257149A2 (en) 2023-10-11
US20190060409A1 (en) 2019-02-28
SG11201806140SA (en) 2018-08-30
PH12018501688A1 (en) 2019-05-27
HUE064432T2 (hu) 2024-03-28
CA3012759A1 (en) 2017-08-31
PL3791860T3 (pl) 2024-03-18
LT3791860T (lt) 2023-12-11
AR107782A1 (es) 2018-06-06
KR102756413B1 (ko) 2025-01-16
PL3419595T3 (pl) 2021-06-14
IL260626A (da) 2018-09-20
FI3791860T3 (fi) 2024-01-11
MD3791860T2 (ro) 2024-03-31
JOP20170046B1 (ar) 2021-08-17
AU2017222292B2 (en) 2021-12-16
MX2018010201A (es) 2019-06-06
EP3419595B1 (en) 2021-01-06
MA52595A (fr) 2021-03-17
MA43686B1 (fr) 2021-03-31
CN108883061B (zh) 2021-06-08
HRP20231477T1 (hr) 2024-03-01
MX381709B (es) 2025-03-13
RS64929B1 (sr) 2023-12-29
DK3791860T3 (da) 2023-12-18
EA036383B1 (ru) 2020-11-03
BR112018015166A2 (en) 2018-12-18
EP4257149A3 (en) 2023-12-20
KR20180114178A (ko) 2018-10-17
SI3419595T1 (sl) 2021-04-30
ZA201804944B (en) 2023-02-22
MY193138A (en) 2022-09-26
LT3419595T (lt) 2021-03-10
CN113398250A (zh) 2021-09-17
HRP20210367T1 (hr) 2021-04-16
AU2022200027A1 (en) 2022-02-03
EA201891905A1 (ru) 2019-02-28
MD3419595T2 (ro) 2021-06-30
TW201733612A (zh) 2017-10-01
CO2018007810A2 (es) 2018-10-22
US20250352621A1 (en) 2025-11-20
SI3791860T1 (sl) 2024-01-31
JP2019507153A (ja) 2019-03-14
IL260626B2 (en) 2023-08-01
TN2018000284A1 (en) 2020-01-16
TWI755377B (zh) 2022-02-21
EP3791860B1 (en) 2023-10-11
WO2017144659A1 (en) 2017-08-31
HUE053492T2 (hu) 2021-06-28
CL2018001984A1 (es) 2018-09-14
US11666635B2 (en) 2023-06-06
AU2017222292A1 (en) 2018-07-26
IL260626B1 (en) 2023-04-01
US20210236600A1 (en) 2021-08-05
US20230372447A1 (en) 2023-11-23
EP3419595A1 (en) 2019-01-02
UA123107C2 (uk) 2021-02-17
ES2966262T3 (es) 2024-04-19
NZ744294A (en) 2024-08-30
PH12018501688B1 (en) 2023-08-02
CN113398250B (zh) 2024-02-23
DK3791860T5 (da) 2024-08-19
ES2862193T3 (es) 2021-10-07
MA52595B1 (fr) 2023-12-29
MA43686A (fr) 2019-01-02
US12447196B2 (en) 2025-10-21
JP2023164573A (ja) 2023-11-10
RS61604B1 (sr) 2021-04-29

Similar Documents

Publication Publication Date Title
DK3337502T3 (da) Stabil anti-ifnar1-formulering
DK3606504T5 (da) Stabil antistofformulering
IL264105A (en) Nutritional formula
EP3905900C0 (en) LIQUID NICOTINE FORMULATION
DK3236749T3 (da) Flydende tribenuron-holdige herbicidsammensætninger
DK3479819T3 (da) Stabilt væskeformigt farmaceutisk præparat
HUE045303T2 (hu) RPL554-et tartalmazó folyékony inhalációs készítmény
DK3496551T3 (da) Flydende allulosesammensætning
DK3226894T3 (da) Stabile flydende vacciniavirus-formuleringer
EP3496773C0 (en) WETTING AGENT FORMULATION
PT3334747T (pt) Formulação de gonadotrofina líquida estável
PL3703518T3 (pl) Formulacja ulegająca aerozolowaniu
DK3791860T3 (da) Stabil væskeformig gonadotropinformulering
IL271892B1 (en) Stable cannabinoid compositions
IL258744B (en) An improved herbicidal formulation
EP3638322A4 (en) DECONTAMINATION FORMULATION
DK3173071T4 (da) Maropitantformulering
CL2016002705A1 (es) Formulación agroquímica
DK3148513T3 (da) Ceritinib-formulering
FR3021528B1 (fr) Formulation cosmetique
EP3368013C0 (en) LIQUID FORMULATIONS OF BUPRENORPHINE
EP3471546A4 (en) INSECTICIDE FORMULATION
HUE066130T2 (hu) Duddingtonia flagranst tartalmazó készítmény
ITUA20163470A1 (it) Formulazione antiappannante
EP3815704A4 (en) FORMULATION CONTAINING EMRICASAN